Provided by Tiger Trade Technology Pte. Ltd.

DUALITYBIO-B

170.300
-13.600-7.40%
Volume:1.38M
Turnover:240.08M
Market Cap:15.47B
PE:-3.66
High:182.200
Open:181.500
Low:170.000
Close:183.900
52wk High:563.500
52wk Low:158.500
Shares:90.83M
HK Float Shares:90.83M
Volume Ratio:1.53
T/O Rate:1.52%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-46.485
ROE:-65.93%
ROA:-24.28%
PB:9.13
PE(LYR):-3.66
PS:15.73

Loading ...

Movement Alert|DUALITYBIO-B Drops 5.38% in Regular Trading, Weak Interim Results and Biotech Sector Selloff Weigh on Shares

Market Focus
·
Yesterday

DUALITYBIO-B: DualityBio Ltd. Acquires Shares, Long Position Rises to 7.19%

HK Disclosure
·
Sep 08

Duality Biotherapeutics, Inc. - B: DualityBio Ltd. Acquires Shares, Long Position Rises to 7.2%

HK Disclosure
·
Sep 08

Hong Kong Stock Movement | DUALITYBIO-B (09606) Climbs Over 4% in Late Trading, New BD Breakthrough with Roche, Potential Milestone Payments Exceed $1 Billion

Stock News
·
Sep 08

Chairman and CEO Acquires Additional Shares in DualityBio Over Two Consecutive Sessions

Stock News
·
Sep 07

DUALITYBIO-B: Zhu Zhongyuan Acquires Shares, Long Position Rises to 17.58%

HK Disclosure
·
Sep 07

DUALITYBIO-B (09606) Surges 6% in Afternoon Trade as BD Deals Exceed $7 Billion and Company Eyes US Development Role

Stock News
·
Sep 03

Movement Alert|DUALITYBIO-B Rises 5.45% in Regular Trading, Multiple Brokers Maintain Buy Ratings Triggering Oversold Rebound

Market Focus
·
Sep 03

DualityBio Signs Genentech ADC Collaboration, Secures USD 45 Million Upfront, over USD 1 Billion Milestones

Reuters
·
Sep 01

Movement Alert|DUALITYBIO-B Falls 7.29% in Regular Trading, H1 Revenue Plunges as Adjusted Net Profit Swings to Loss

Market Focus
·
Aug 31

Duality Biotherapeutics (SEHK:9606) Stock Grapples With Revenue Collapse And Heavy Losses

Simply Wall St.
·
Aug 30

Duality Biotherapeutics Inc - Board Does not Recommend Payment of Interim Dividends

THOMSON REUTERS
·
Aug 28

Duality Biotherapeutics, Inc Hy Adjusted Loss Rmb626.9 Mln

THOMSON REUTERS
·
Aug 28

Duality Biotherapeutics FY26 H1 Loss Narrows to RMB 917.55 Million; Revenue Drops 82.16% to RMB 219.33 Million

Reuters
·
Aug 28

Duality Biotherapeutics Ties Up With Genentech to Develop Oncology Drugs

MT Newswires Live
·
Aug 28

Duality Biotherapeutics Rises Most in Near Six Weeks on Roche's Genentech Tie-up

Reuters
·
Aug 28

Dualitybio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation Adcs Built on Dualitybio's Dupac Novel-Payload Platform

THOMSON REUTERS
·
Aug 28

DUALITYBIO-B Surges Nearly 6% Following Genentech Licensing Pact

Deep News
·
Aug 28

Movement Alert|DUALITYBIO-B Rises 5.27% in Regular Trading, Signs Global ADC R&D Collaboration with Genentech Securing $45M Upfront Payment

Market Focus
·
Aug 28

Hong Kong Market Movers: Mixue's Revenue Reaches RMB 15.2 Billion in First Half, Global Store Network Expands

Stock News
·
Aug 28